<DOC>
	<DOCNO>NCT00956163</DOCNO>
	<brief_summary>This phase 0 trial study whole body fluorine F 18 sodium fluoride positron emission tomography ( PET ) /computed tomography ( CT ) scan whole body magnetic resonance imaging ( MRI ) find bone metastases patient prostate cancer . Diagnostic procedure , whole body fluorine F 18 sodium fluoride PET/CT scan whole body MRI , may help find diagnose bone metastasis .</brief_summary>
	<brief_title>Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan Whole Body MRI Finding Bone Metastases Patients With Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate sensitivity specificity whole-body fluorine F 18 sodium fluoride PET/CT scan detect bone metastases patient high-risk prostate cancer use bone scan reference standard . II . To evaluate sensitivity specificity whole-body MRI detect bone metastases patient high-risk prostate cancer use bone scan reference standard . OUTLINE : Patients undergo technetium Tc 99m methylene diphosphonate bone scan , fluorine F 18 sodium fluoride PET/CT scan , whole-body MRI detection bone metastasis . Patients discordant imaging result ( negative bone scan positive PET/CT scan and/or MRI ) undergo additional imaging 6 , 12 , 18 , 24 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Sodium Fluoride</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<mesh_term>Listerine</mesh_term>
	<mesh_term>Technetium Tc 99m Medronate</mesh_term>
	<mesh_term>Methylene diphosphonate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Any ethnic group Pathologically proven prostate cancer high risk bone metastases Rising prostatespecific antigen ( PSA ) despite androgen deprivation therapy ( ADT ) , PSA &gt; 10 ng/mL Ability understand willingness sign write combine Health Insurance Portability Accountability Act ( HIPAA ) inform consent document Patients Eastern Cooperative Oncology Group ( ECOG ) performance = &lt; 1 Patients may receive investigational therapeutic agent within 7 day prior study drug administration 7 day follow study drug administration Patients known contraindication MR image presence MRI incompatible device pacemaker certain aneurysm clip , severe claustrophobia , condition would preclude proximity strong magnetic field ; exclusion standard practice Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; patient category exclude reduce medical risk safety avoid confound variable regard possibility adverse event Patient unable tolerate lifer threaten allergy radiopharmaceutical use bone scan 18Ffluoride PET</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>